Full text is available at the source.
Abstract
The FDA has approved two new medications for advanced metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis.
- Incretin-based therapies, such as GLP-1 receptor agonists, may offer benefits for individuals with both MASH and obesity or type 2 diabetes.
- These medications could improve metabolic functions by affecting glucose and fat processing in the body.
- Potential cardiovascular and kidney benefits are associated with the use of these agents.
- Challenges persist regarding how long treatments should be taken, their tolerability, and the differences in how individuals respond to therapy.
- Evidence from phase 2 and phase 3 clinical trials indicates that these therapies may positively affect liver health as assessed by histology.
Simplified